The life sciences industry is increasingly addressing lifethreatening diseases with sophisticated and complex protein therapeutics, such as novel scaffolds, fusion proteins, bi-specific proteins, and cytotoxic cytokines and interferons. These next-generation therapeutics, which are often difficult-to-express proteins, have been accompanied by a new set of challenges with regard to their manufacturing. Generating manufacturing cell lines that secrete high levels of intact recombinant therapeutic proteins requires more than effective and stable integration of the recombinant gene into the manufacturing cell’s genome…
Obtaining the Optimal Clone: Exploiting metabolic selection in mammalian cells for clonal enrichment, particularly for difficult-to-express proteins.
Posted by
Selexis admin on Nov 21, 2017 12:00:00 AM
November 21, 2017